HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Subgroup Analysis

**BACKGROUND**

- Inhibitor of HIV-1 attachment, active metabolite linked to BMS-663068 dose escalation study.
- Single-dose safety, tolerability and antiretroviral activity in healthy volunteers and antiretroviral-experienced subjects.

**METHOD**

- Phase 2 study (NCT01384734; EudraCT 2011-000437-36), investigating the efficacy, safety and dose response of BMS-663068.
- Subjects had ≥2 active antiretroviral classes.
- BMS-663068 monotherapy substudy: 10 patients per study arm.

**RESULTS**

- Observed analysis: Figure 4.
- Modified intent-to-treat analysis: BMS-663068 400 mg BID, 82%; 800 mg BID, 61%; 600 mg QD, 73%.

**ACKNOWLEDGMENTS**

- Bristol-Myers Squibb, Wallingford, CT, USA; University of Cincinnati, Cincinnati, OH, USA.

**REFERENCES**

11. ACKNOWLEDGMENTS

**CONCLUSION**

- These data support the ongoing Phase III trial evaluating BMS-663068 for use in heavily treatment-experienced subjects.